We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zhejiang Huahai

News List

Valsartan recall expands to Mylan, Teva products fiercepharma
December 06, 2018
When a suspected carcinogen was detected by a U.S. drugmaker last summer in the API it had acquired to make blood pressure drugs, it first appeared to be another issue of tainted products produced in China. Since then
Litigation teaches Chinese valsartan maker the downside of U.S. market fiercepharma
October 10, 2018
China’s Zhejiang Huahai Pharmaceutical for years enjoyed the upside of the U.S. pharmaceutical market, selling its valsartan API to drugmakers producing blood pressure meds for the market.
FDA berates Chinese drugmaker tied to global valsartan recall fiercepharma
September 30, 2018
The FDA last month went back into China's Zhejiang Huahai Pharmaceutical and produced a Form 483 with observations that strike at the heart of its manufacturing changes.
EU regulators blast China’s Zhejiang Huahai over valsartan API mess fiercepharma
September 29, 2018
The European Medicines Agency has piled onto China’s Zhejiang Huahai, finding its manufacturing out of compliance for the valsartan API that has been recalled globally after being found to contain a suspected carcinogen.